Femasys (NASDAQ:FEMY) Releases Earnings Results, Misses Estimates By $0.04 EPS

by · The Cerbat Gem

Femasys (NASDAQ:FEMY – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04), Zacks reports. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 120.13%. The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million.

Femasys Stock Performance

NASDAQ:FEMY opened at $1.03 on Thursday. Femasys has a 12 month low of $0.73 and a 12 month high of $2.40. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $22.90 million, a price-to-earnings ratio of -1.27 and a beta of -2.83. The firm has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.15.

Analyst Upgrades and Downgrades

FEMY has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Femasys in a report on Tuesday. Chardan Capital decreased their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday.

Get Our Latest Stock Report on FEMY

Femasys Company Profile

(Get Free Report)

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

See Also